A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol * Written informed consent obtained from the subject prior to performing any study specific procedure * A male or female between, and including, 18 and 45 years of age at the time of first vaccination * Healthy subjects as established by medical history and clinical examination before entering into the study * Female subjects of non-childbearing potential may be enrolled in the study * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccina-tion, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series Exclusion Criteria: * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product * Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines, or planned use during the study period * Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to study vaccination, or planned administration during the study period *…